The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients

被引:12
作者
Abubakar, Murtala B. [1 ,2 ]
Wei, Keat [1 ]
Gan, Siew Hua [1 ]
机构
[1] Univ Sains Malaysia, Sch Med Sci, Ctr Human Genome, Kubang Kerian 16150, Kelantan, Malaysia
[2] Usmanu Dan Fodiyo Univ, Coll Hlth Sci, Dept Physiol, Sokoto, Nigeria
关键词
anastrozole; breast cancer; polymorphisms; postmenopausal; ESTROGEN-RECEPTOR-BETA; BONE-MINERAL DENSITY; ADJUVANT ENDOCRINE THERAPY; AROMATASE INHIBITORS; MUSCULOSKELETAL SYMPTOMS; GLUCURONOSYLTRANSFERASE UGT1A4; FUNCTIONAL POLYMORPHISMS; OXIDATIVE-METABOLISM; NEOADJUVANT THERAPY; CONTINUED TAMOXIFEN;
D O I
10.1097/FPC.0000000000000092
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 090105 [作物生产系统与生态工程];
摘要
Breast cancer is a common cause of cancer mortality among women. Several genetic factors have been implicated in its development. Current treatment guidelines for estrogen receptor-positive breast cancer recommend that anastrozole [or any of the other two aromatase inhibitors (letrozole and exemestane)] is used as an alternative to tamoxifen or following several years of tamoxifen treatment. Nevertheless, this approach is still associated with many challenges, ranging from the recurrence of breast cancer to considerable interindividual variability in the tolerability of anastrozole, which may cause adverse effects, such as musculoskeletal symptoms, and lead to the withdrawal of many patients from treatment. Variabilities in the genes encoding the drug target (aromatase) or its metabolizing enzymes (CYP3A and UGT1A) contribute toward the interindividual variability in anastrozole's pharmacokinetics and/or pharmacodynamics. This paper reviews the role of genetic polymorphisms of CYP19A1, CYP3A4, and UGT1A4 in the responses of female hormone receptor-positive postmenopausal breast cancer patients to anastrozole. Many reviews in the literature have suggested that the study of functional polymorphisms and investigation of relevant genetic markers may provide valuable information in predicting responses to anastrozole in terms of its therapeutic and adverse effects. Nevertheless, more studies are required before the knowledge of its pharmacogenomics can be applied to the individualization of treatment to ensure that patients receive the maximum benefits. Therefore, future analyses, including but not limited to genome-wide association studies, are encouraged to address some of the gray areas in the pharmacogenomics of anastrozole therapy in postmenopausal breast cancer cases; this will help in providing guidance for future pharmacogenomics protocols when anastrozole is utilized in patients' management.
引用
收藏
页码:575 / 581
页数:7
相关论文
共 89 条
[1]
UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan [J].
Ando, Y ;
Saka, H ;
Asai, G ;
Sugiura, S ;
Shimokata, K ;
Kamataki, T .
ANNALS OF ONCOLOGY, 1998, 9 (08) :845-847
[2]
[Anonymous], NAT COMPR CANC NETW
[3]
[Anonymous], CAS PERS MED
[4]
[Anonymous], J NATL CANC I
[5]
[Anonymous], 2012, Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012
[6]
AstraZeneca, 2009, AR AN TABL
[7]
A pharmacogenetics study of the human glucuronosyltransferase UGT1A4 [J].
Benoit-Biancamano, Marie-Odile ;
Adam, Jean-Philippe ;
Bernard, Olivier ;
Court, Michael H. ;
Leblanc, Marie-Helene ;
Caron, Patrick ;
Guillemette, Chantal .
PHARMACOGENETICS AND GENOMICS, 2009, 19 (12) :945-954
[8]
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial [J].
Boccardo, F ;
Rubagotti, A ;
Puntoni, M ;
Guglielmini, P ;
Amoroso, D ;
Fini, A ;
Paladini, G ;
Mesiti, M ;
Romeo, D ;
Rinaldini, M ;
Scali, S ;
Porpiglia, M ;
Benedetto, C ;
Restuccia, N ;
Buzzi, F ;
Franchi, R ;
Massidda, B ;
Distante, V ;
Amadori, D ;
Sismondi, P .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5138-5147
[9]
Meta-analysis of vascular and neoplastic events associated with tamoxifen [J].
Braithwaite, RS ;
Chlebowski, RT ;
Lau, J ;
George, S ;
Hess, R ;
Col, NF .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 (11) :937-947
[10]
Aromatase Inhibitor-Associated Arthralgias [J].
Chlebowski, Rowan T. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) :4032-4034